Lymphomas | Clinical

Activity of Brentuximab Vedotin Plus Nivolumab Clinically Meaningful for Subset of Patients with HL

December 07, 2020

The combination of brentuximab vedotin and nivolumab demonstrated activity in patients with previously untreated Hodgkin lymphoma who had comorbidities in a phase 2 clinical trial, despite the trial not meeting its prespecified criteria for activity.

Odronextamab Shows Intriguing Antitumor Activity in Relapsed/Refractory B-Cell NHL

December 06, 2020

Promising antitumor activity, as well as an acceptable safety profile, continues to be demonstrated with odronextamab, a novel CD20xCD3 bispecific antibody, as treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

TTI-622 Demonstrates Safety and Preliminary Activity in R/R Lymphomas

December 06, 2020

In patients with relapsed or refractory lymphoma, treatment with the investigational CD47-blocker TTI-622 appeared well tolerated and demonstrated preliminary activity, according to results from a phase 1a clinical trial presented in a poster during the 2020 American Society of Hematology Virtual Annual Meeting.

Similar 1-Year DFS Observed With Continued Ibrutinib, Following Fixed-Duration of Ibrutinib/Venetoclax Vs Placebo in CLL/SLL

December 05, 2020

Placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Clinical Activity and Durable Responses Observed With MEDI-570 in R/R T-cell Lymphomas

December 05, 2020

In a phase 1 study of patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, the anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 demonstrated activity, durable responses, safety, and tolerability.